retatrutide trial news Amid the growing demand for GLP-1 medications for weight loss, a new experimental drug, retatrutide, stands out, according to new clinical results released on Thursday., ABC News' Youri Results from a new trial

Novo Nordisk expects to present the full results of the trial at a scientific conference later this year

Ultimately, the G/D-CuP group demonstrates superior therapeutic efficacy, achieving 97.2% closure of infected wounds

Pharmaceutical development is a lengthy process, and while early results are promising, several significant milestones must be reached before this medication becomes available to UK patients

Patients typically start with a lower dose of Wegovy, which is gradually increased over 16-20 weeks to minimize potential side effects such as nausea, vomiting, and diarrhea

At $1,000 a month or more, GLP-1s are becoming one of the fastest-growing line items in employer pharmacy budgets

This product should be kept refrigerated